Ingela Wiklund, PhD

Senior Research Leader

Ingela Wiklund, PhD, is a Senior Research Leader based in the London and Sweden offices of United BioSource Corporation (UBC)’s Center for Health Outcomes Research.

Dr Wiklund joined UBC in 2009 after 2.5 years as Director Patient Reported Outcomes, GlaxoSmithKline (GSK), London, UK. Previously, she worked for more than 17 years with AstraZeneca (AZ) in Sweden, most recently as Global Director of Outcomes Research. In both roles, she provided strategic direction and implemented outcomes research activities across a broad range of therapeutic areas, overseeing all interactions with regulatory bodies to ensure best practice in meeting the regulatory guidance criteria, and championing the use and evolution of ePROs and other electronic data capture.

After completing a Masters degree in Psychology at Gothenburg University, Dr. Wiklund completed her postgraduate training at the Department of Medicine and Rehabilitation Medicine. She has worked as a Clinical Psychologist in the departments of Neurosurgery, Neurology, Rehabilitation Medicine, and Outpatient Psychiatry at Sahlgrenska University Hospital in Gothenburg, Sweden; currently, she is Associate Professor of Rehabilitation Medicine. Previously, she was Professor of Health Care Research at Bergen University, Norway. Dr. Wiklund has been actively involved in the ERIQA Group, Harmonizing Quality of Life Research in Europe, and has served on the ISPOR PRO translations task-force as well as in the FDA PRO - Harmonization Group. She co-chaired the PRO group within the Innovative Medicines Initiative (IMI) in COPD, and was the GSK representative in the EXACT PRO COPD consortia.

Dr. Wiklund has developed several PRO instruments for use in hypertension, heart failure, angina pectoris, growth hormone insufficiency, vasomotor symptoms, and more recently, PROs for use in patients with muscosceletal disorders and inflammatory diseases, GERD and dyspepsia, IBS, and COPD. She has authored more than 200 peer-reviewed publications on burden of illness, instrument development, methodological and regulatory issues in papers such as Hypertension, American Heart Journal, Controlled Clinical Trials, Circulation, European Heart Journal, European Journal of Clinical Pharmacology, Journal of Clinical Epidemiology, and Quality of Life Research, and has presented at numerous scientific and industry conferences around the world.

Close window